Infomail Archive

Infomail 2004 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Dec 31: FDA to review “missing” drug company documents Dec 30: Family of Woman Killed by AIDS Drug Test Sues Doctors, Manufacturer Dec 30: Doctors, Too, Ask: Is . . . Continue reading →

What Parents Aren’t Being told about their Kids Antidepressants – A Suicide Side-Effect? – SF Chronicle

What Parents Aren’t Being told about their Kids Antidepressants – A Suicide Side-Effect? – SF Chronicle Sat, 10 Jan 2004 An in-depth article in The San Francisco Chronicle reveals how the hidden hazards of SSRIs put adolescents’ lives in danger. For one . . . Continue reading →

Paxil induced suicides in US quantified_Glaxo Faces criminal action in UK over "suicide" pills_Times

Paxil induced suicides in US quantified_Glaxo Faces criminal action in UK over “suicide” pills_Times Mon, 7 Jun Law enforcement is finally catching up with drug companies who, for years, concealed evidence of a drug-related suicide risk for some children and adults who . . . Continue reading →

Prescription Drug Industfry: The Insiders – AARP Bulletin

Prescription Drug Industfry: The Insiders – AARP Bulletin Wed, 10 Nov 2004 Three pharmaceutical industry insiders blow the whistle in one of the most important articles you’ll ever read about the unethical marketing of prescription drugs. Peter Rost, M.D, a top marketing . . . Continue reading →

Hoffman LaRoche Rebuffed Call to Monitor Accutane Users – USA Today

Hoffman LaRoche Rebuffed Call to Monitor Accutane Users – USA Today Tue, 7 Dec 2004 An investigative cover story in USA Today – Drugmaker Rebuffed Call to Monitor Users–affirms the indispensable role of litigation in bringing the facts about adverse drug effects . . . Continue reading →

Advisory Committee tells FDA: strengthen warnings on SSRI drug labels now

Advisory Committee tells FDA: strengthen warnings on SSRI drug labels now Wed, 4 Feb 2004 On February 2, more than 60 families and children from all across America testified at a public FDA advisory committee hearing describing (in 2 minutes) how their . . . Continue reading →